Pfizer Inc. (PFE)
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, and manufactures a wide range of medicines and vaccines. With a history dating back to 1849, Pfizer operates worldwide, offering products across various therapeutic areas.
Company Overview
Pfizer Inc. (PFE) is a global pharmaceutical leader with a diverse portfolio of innovative medicines and vaccines, a robust pipeline, and a strong dividend yield of 6.32%, making it an attractive investment for long-term growth and income in the healthcare sector.
Investment Thesis
Pfizer presents a compelling investment opportunity due to its diverse product portfolio, strong pipeline, and attractive dividend yield of 6.32%. With a market capitalization of $154.76 billion and a P/E ratio of 19.91, Pfizer demonstrates financial stability and profitability, supported by a gross margin of 70.3% and a profit margin of 12.4%. Key value drivers include continued growth in key therapeutic areas, successful pipeline development, and strategic collaborations. Upcoming catalysts include potential regulatory approvals for new drugs and vaccines, as well as expansion into new markets. The company's commitment to innovation and its established global presence position it for sustained growth and value creation.
Key Highlights
- Market capitalization of $154.76 billion, reflecting its significant presence in the pharmaceutical industry.
- P/E ratio of 19.91, indicating a reasonable valuation relative to earnings.
- Gross margin of 70.3%, showcasing efficient production and pricing strategies.
- Dividend yield of 6.32%, offering an attractive income stream for investors.
- Beta of 0.44, suggesting lower volatility compared to the overall market.
Competitors
Strengths
- Diverse product portfolio across multiple therapeutic areas.
- Strong financial performance and profitability.
- Extensive global presence and distribution network.
- Robust research and development pipeline.
Weaknesses
- Reliance on key products with patent expirations.
- Exposure to regulatory risks and pricing pressures.
- Dependence on successful clinical trial outcomes.
- Potential for product liability claims.
Catalysts
- Upcoming: Regulatory approvals for new drug candidates in the pipeline.
- Ongoing: Expansion of the vaccine portfolio to address emerging infectious diseases.
- Ongoing: Strategic collaborations and acquisitions to enhance product offerings.
- Ongoing: Growth in emerging markets with increasing healthcare spending.
Risks
- Potential: Patent expirations of key products leading to generic competition.
- Potential: Unsuccessful clinical trial outcomes for drug candidates.
- Ongoing: Regulatory risks and pricing pressures affecting profitability.
- Ongoing: Product liability claims and litigation.
Growth Opportunities
- Expansion of Vaccine Portfolio: Pfizer has the opportunity to expand its vaccine portfolio beyond COVID-19, targeting other infectious diseases with unmet needs. The global vaccine market is projected to reach $100 billion by 2025, driven by increasing awareness of preventative healthcare and government initiatives. Pfizer's established infrastructure and expertise in vaccine development provide a competitive advantage in capturing a significant share of this market. Timeline: Ongoing.
- Development of Novel Therapies: Pfizer can drive growth by focusing on the development of novel therapies in areas such as oncology, immunology, and rare diseases. These therapeutic areas represent significant market opportunities with high unmet needs. Successful development and commercialization of innovative therapies can drive revenue growth and enhance Pfizer's market position. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: Pfizer can pursue strategic acquisitions and partnerships to expand its product portfolio and access new technologies. By acquiring companies with promising drug candidates or innovative platforms, Pfizer can accelerate its growth and diversify its revenue streams. This strategy allows Pfizer to leverage external innovation and strengthen its competitive position. Timeline: Ongoing.
- Emerging Markets Expansion: Pfizer has the opportunity to expand its presence in emerging markets, where healthcare spending is increasing rapidly. These markets offer significant growth potential due to rising incomes, expanding access to healthcare, and increasing prevalence of chronic diseases. By tailoring its product offerings and distribution strategies to meet the specific needs of these markets, Pfizer can drive revenue growth and establish a strong foothold. Timeline: Ongoing.
- Biosimilars Market: Pfizer can capitalize on the growing biosimilars market, offering cost-effective alternatives to branded biologic drugs. As patents for biologic drugs expire, biosimilars provide an opportunity to capture market share and generate revenue. Pfizer's expertise in biologics manufacturing and regulatory affairs positions it to compete effectively in this market. The global biosimilars market is expected to reach $35 billion by 2027. Timeline: Ongoing.
Opportunities
- Expansion into emerging markets with growing healthcare needs.
- Development of novel therapies for unmet medical needs.
- Strategic acquisitions and partnerships to expand product portfolio.
- Growth in the biosimilars market.
Threats
- Competition from other pharmaceutical companies.
- Generic erosion of key products.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Patent protection for its innovative drugs, providing market exclusivity.
- Strong brand recognition and reputation for quality and efficacy.
- Extensive global distribution network, enabling access to markets worldwide.
- Significant investment in research and development, driving innovation and new product development.
About
Founded in 1849 in New York City, Pfizer Inc. has evolved into one of the world's premier biopharmaceutical companies. Initially focused on producing fine chemicals, Pfizer quickly adapted to changing market needs, expanding its research and development efforts to create innovative medicines and vaccines. Today, Pfizer discovers, develops, manufactures, markets, and sells a broad range of products across various therapeutic areas. These include cardiovascular metabolic and women's health solutions like the Premarin family and Eliquis, as well as biologics, small molecules, immunotherapies, and biosimilars under brands such as Ibrance, Xtandi, and the Prevnar family. The company also offers sterile injectable and anti-infective medicines, including the oral COVID-19 treatment Paxlovid. Pfizer serves a global market, reaching wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices. Through strategic collaborations with companies like Bristol-Myers Squibb and BioNTech SE, Pfizer continues to innovate and expand its product offerings, solidifying its position as a leader in the pharmaceutical industry. Pfizer's commitment to research and development, combined with its global reach, positions it to address unmet medical needs and drive future growth.
What They Do
- Discovers novel pharmaceutical compounds and vaccines.
- Develops and tests new medicines through clinical trials.
- Manufactures pharmaceutical products on a large scale.
- Markets and sells medicines and vaccines globally.
- Distributes products through wholesalers, retailers, and healthcare providers.
- Conducts research to improve existing treatments and develop new ones.
- Collaborates with other companies and research institutions.
Business Model
- Develops and patents pharmaceutical products.
- Generates revenue through the sale of patented and generic drugs.
- Invests heavily in research and development to create new products.
- Partners with other companies to expand its product portfolio and market reach.
Industry Context
Pfizer operates in the highly competitive global pharmaceutical industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The industry is experiencing growth driven by an aging global population, increasing prevalence of chronic diseases, and advancements in biotechnology. Pfizer competes with other major pharmaceutical companies, including Amgen (AMGN) and Bristol-Myers Squibb (BMY), focusing on innovative therapies and strategic partnerships. The market is also influenced by trends such as personalized medicine, biosimilars, and digital health solutions. Pfizer's diverse portfolio and global reach position it to capitalize on these trends and maintain its competitive edge.
Key Customers
- Wholesalers and distributors of pharmaceutical products.
- Hospitals and clinics.
- Pharmacies and retailers.
- Government agencies and healthcare organizations.
- Individual patients through prescriptions.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $17.56B | -$1648M | $0.00 |
| Q3 2025 | $16.65B | $3.54B | $0.00 |
| Q2 2025 | $14.65B | $2.91B | $0.00 |
| Q1 2025 | $13.71B | $2.97B | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Pfizer Inc. (PFE) stock price: $26.45 (+0.60, +2.32%)
Why Bull
- •Recent insider buying suggests confidence in Pfizer's upcoming product pipeline, particularly in vaccines and therapeutics.
- •Community sentiment has shifted positively, with discussions highlighting Pfizer's potential in expanding its mRNA technology beyond COVID-19.
- •Analysts are optimistic about the company's strategic partnerships, which could enhance its research capabilities and market reach.
- •Pfizer's strong historical performance in managing drug approvals and navigating regulatory landscapes bolsters investor trust.
Why Bear
- •Concerns over patent expirations and the potential impact on revenue from key drugs are weighing on investor sentiment.
- •Community discussions reflect skepticism about the sustainability of Pfizer's growth post-pandemic, with doubts about future vaccine demand.
- •Recent regulatory challenges faced by Pfizer in certain markets have raised alarms regarding operational risks and profitability.
- •Some analysts express caution regarding competitive pressures in the pharmaceutical sector, particularly from generics and biosimilars.
Latest News
-
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday
benzinga · Feb 20, 2026
-
Barclays launches U.S. biopharma coverage with four preferred picks
Investing.com · Feb 20, 2026
-
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading
GlobeNewswire · Feb 20, 2026
-
Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading
GlobeNewswire · Feb 20, 2026
Technical Analysis
Rationale
AI-generated technical analysis for PFE including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Pfizer Inc. (PFE) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for PFE.
Make a Prediction
Set your price target for Pfizer Inc. (PFE), choose a timeframe, and track your prediction accuracy.
Current price: $26.45
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PFE.
Price Targets
Wall Street price target analysis for PFE.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -1.6% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 10/100
Gross margin of 70.3% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 7/100
R&D at 19.1% of revenue shows meaningful innovation investment, typical of growth-oriented tech companies.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 0.90% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
News sentiment is mixed, with a balance of positive and negative coverage in recent days.
What does this score mean?
The MoonshotScore rates PFE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday
Barclays launches U.S. biopharma coverage with four preferred picks
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading
Tobacco Alternative Gums Analysis Report 2026-2035: A $4.25 Billion Market by 2030 with CVS Health, The Kroger Co., Walgreens Boots Alliance, along with Pfizer, Johnson & Johnson Leading
Frequently Asked Questions
What does Pfizer Inc. do?
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and sells a wide range of medicines and vaccines. Its diverse product portfolio includes treatments for cardiovascular metabolic and women's health, biologics, immunotherapies, and biosimilars. Pfizer serves a global market, reaching wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices. The company's commitment to research and development, combined with its global reach, positions it to address unmet medical needs and drive future growth in the pharmaceutical industry.
Is PFE stock a good buy?
Pfizer's stock presents a mixed outlook. Its attractive dividend yield of 6.32% and established market position offer stability. However, investors should consider potential risks such as patent expirations and regulatory pressures. Growth opportunities in emerging markets and novel therapies could drive future value. A balanced approach considering both the income potential and growth prospects is essential for determining if PFE is a suitable investment, alongside monitoring its pipeline progress and financial performance.
What are the main risks for PFE?
Pfizer faces several key risks, including patent expirations on blockbuster drugs, leading to generic competition and revenue decline. Regulatory challenges and pricing pressures in the pharmaceutical industry can also impact profitability. Additionally, the success of Pfizer's pipeline depends on positive clinical trial outcomes, which are inherently uncertain. Product liability claims and litigation represent ongoing risks. These factors could affect Pfizer's financial performance and market valuation. Careful monitoring of these risks is crucial for investors.
Is PFE a good stock to buy?
Whether PFE is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the PFE MoonshotScore?
The MoonshotScore for PFE is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is PFE data updated?
PFE stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to PFE is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for PFE?
Growth catalysts for Pfizer Inc. (PFE) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Pfizer Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are PFE's main competitors?
Pfizer Inc. (PFE) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether PFE has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about PFE?
Wall Street analyst coverage for PFE includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is PFE's market cap?
Market capitalization (market cap) for PFE is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows PFE's current market cap alongside enterprise value and other valuation metrics.
How has PFE stock performed recently?
PFE's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing PFE's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in PFE?
Key risk categories for PFE include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures PFE's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling PFE?
Insider trading activity for PFE tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is PFE a good stock for beginners?
Pfizer Inc. (PFE) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is PFE for first-time investors?
Every stock carries risk, including Pfizer Inc. (PFE). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like PFE.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.